Table 1.
Patient and SBRT characteristics
| All patients | Central-abutting tumors |
Nonabutting central tumors |
GTV ≤1 cm from PBT |
GTV >1 cm from PBT |
|
|---|---|---|---|---|---|
| Value or number (%) | |||||
| Number of patients | 108 | 18 | 90 | 26 | 82 |
| Age, median, y (range) | 77.5 (49–95) | 69 (49–84) | 79 (52–95) | 69 (49–87) | 79 (52–95) |
| Sex | |||||
| Male | 53 (49) | 7 (39) | 46 (51) | 9 (35) | 44 (54) |
| Female | 55 (51) | 11 (61) | 44 (49) | 17 (65) | 38 (46) |
| Karnofsky Performance Status | |||||
| ≥80% | 78 (72) | 15 (83) | 63 (70) | 21 (81) | 57 (70) |
| <80% | 30 (28) | 3 (17) | 27 (30) | 5 (19) | 25 (30) |
| Primary site | |||||
| Lung | 101 (93) | 17 (94) | 84 (93) | 22 (85) | 80 (98) |
| Colorectal | 2 (2) | 1 (6) | 1 (1) | 1 (4) | 0 (0) |
| Uterine | 2 (2) | 0 (0) | 2 (2) | 2 (8) | 0 (0) |
| Head and neck | 2 (2) | 0 (0) | 2 (2) | 0 (0) | 2 (2) |
| Hepatobiliary | 1 (1) | 0 (0) | 1 (1) | 1 (4) | 0 (0) |
| Lung lesion site | |||||
| RUL | 29 (27) | 4 (22) | 25 (28) | 7 (27) | 22 (27) |
| RML | 8 (7) | 2 (11) | 6 (7) | 3 (12) | 5 (6) |
| RLL | 17 (16) | 4 (22) | 13 (14) | 5 (19) | 12 (15) |
| R hilar | 2 (2) | 2 (11) | 0 (0) | 2 (8) | 0 (0) |
| LUL | 27 (25) | 2 (11) | 25 (28) | 3 (12) | 24 (29) |
| LLL | 24 (22) | 4 (22) | 20 (22) | 5 (19) | 19 (23) |
| L Hilar | 1 (1) | 0 (0) | 1 (1) | 1 (4) | 0 (0) |
| Tumor histology | |||||
| Adenocarcinoma | 77 (71) | 8 (44) | 69 (77) | 14 (54) | 63 (77) |
| Squamous cell | 25 (23) | 8 (44) | 17 (19) | 9 (35) | 16 (20) |
| Other | 6 (6) | 2 (11) | 4 (4) | 3 (12) | 3 (4) |
| TNM status (n = 88) a | |||||
| T1N0M0 | 66 (75) | 8 (67) | 58 (76) | 11 (65) | 55 (77) |
| T2N0M0 | 22 (25) | 4 (33) | 18 (24) | 6 (35) | 16 (23) |
| Lung lesion greatest dimension | |||||
| ≤ 2 cm | 43 (40) | 5 (28) | 38 (42) | 8 (31) | 35 (43) |
| >2 to ≤ 3 cm | 36 (33) | 7 (39) | 29 (32) | 9 (35) | 27 (33) |
| >3 to ≤ 5 cm | 27 (25) | 6 (33) | 21 (23) | 9 (35) | 18 (22) |
| >5 cm | 2 (2) | 0 (0) | 2 (2) | 0 (0) | 2 (2) |
| Prescription dose | |||||
| 4500 cGy in 5 fx | 60 (56) | 14 (78) | 46 (51) | 21 (81) | 39 (48) |
| 5000 cGy in 5 fx | 19 (18) | 4 (22) | 15 (17) | 4 (15) | 15 (18) |
| 4800 cGy in 4 fx | 18 (17) | 0 (0) | 18 (20) | 1 (4) | 17 (21) |
| 5400 cGy in 3 fx | 7 (7) | 0 (0) | 7 (8) | 0 (0) | 7 (9) |
| 6000 cGy in 3 fx | 2 (2) | 0 (0) | 2 (2) | 0 (0) | 2 (2) |
| 4400 cGy in 4 fx | 1 (1) | 0 (0) | 1 (1) | 0 (0) | 1 (1) |
| 3600 cGy in 2 fx | 1 (1) | 0 (0) | 1 (1) | 0 (0) | 1 (1) |
| BED10, median (range) | 85.5 (85.5–180) | 85.5 (85.5–100) | 85.5 (85.5–180) | 85.5 (85.5–105.6) | 100 (85.5–180) |
| VEGF inhibitor therapy | 10 (9) | 4 (22) | 6 (7) | 6 (23) | 4 (5) |
BED = biologically effective dose; cGy = centigray; fx = fractions; L, left; LUL, left upper lobe; R, right; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe; VEGF = vascular endothelial growth factor.
a
For 88 patients with primary lesions, classified according to the seventh edition (2010) of the American Joint Committee on Cancer staging manual.